Targeted delivery of PERK inhibitors, such as AMG-44 or GSK2606414, to the spleen using a micro-osmotic pump system resulted in effective tumor control, significantly more than direct delivery to the tumors, emphasizing the detrimental role of PERK activation in splenic MDSCs [183]. Here, EIF2AK3 is linked to neoplasm.